Cytiva Acquires Aseptic Filling Firm Vanrx Pharmasystems
Source: Vanrx Pharmasystems
February 4, 2021
Cytiva acquired Vanrx Pharmasystems, a Canadian company that makes robotic aseptic filling machines to fill vials, syringes, and cartridges. The deal marks the first acquisition by Cytiva.
“Since becoming a Danaher operating company in April 2020, we have already begun fueling innovation and re-investing in the business for the benefit of our customers and their patients,” says Emmanuel Ligner, president and CEO of Cytiva. “We are thrilled to welcome the Vanrx associates to our family and look forward to working together on delivering meaningful solutions for biomanufacturers.”
The Vanrx portfolio complements Cytiva’s manufacturing capacity solutions, according to Ligner, adding that while great progress has until now focused on drug substances, this innovation is focused on drug product, which he calls a “critical last step” before distribution to patients.
Published: Feb 04, 2021 By Alex Keown
China’s JW Therapeutics, which was co-founded by Juno Therapeutics and Wuxi AppTec, forged a partnership with Thermo Fisher Scientific to ensure non-exclusive
commercial access to Thermo Fisher’s Gibco CTS Dynabeads CD3/CD28. The exclusive agreement will be used to support JW’s clinical development programs for CAR-T (Chimeric Antigen Receptor T-Cells) therapies in China. The deal includes JW Therapeutics’ lead product relmacabtagene
autoleucel (relma-cel), which is an anti-CD19 CAR-T therapy for third-line treatment for relapsed or refractory B-cell lymphoma. The therapy’s new drug application has been accepted by China s National Medical Products Administration. Relma-cel is expected to be the first CAR-T therapy to be approved as a Category 1 biologics product in China.
Cytiva acquires Vanrx Pharmasystems, Canadian aseptic filling innovator
USA - English
Share this article
- Addition to portfolio supports global trends towards smaller manufacturing and the advent of personalized therapies
- First acquisition by company since becoming Cytiva in April 2020
AMERSHAM, United Kingdom, Feb. 1, 2021 /PRNewswire/ Cytiva has acquired Vanrx Pharmasystems, a Canadian company that makes robotic aseptic filling machines to fill vials, syringes, and cartridges with reduced risk and increased speed to patients.
SA25 Front Operator (PRNewsFoto/Cytiva)
This is the first acquisition by Cytiva. Emmanuel Ligner, President and CEO, Cytiva, says: Since becoming a Danaher operating company in April 2020, we have already begun fueling innovation and re-investing in the business for the benefit of our customers and their patients. We are thrilled to welcome the Vanrx associates to our family and look forward to working together on delivering meaningful soluti
01 febbraio 2021 06:48
Fonte: Adnkronos
#salute-e-benessere
- Cytiva will now provide idea to injection solutions to customers and the market
- Addition to portfolio supports global trends towards smaller manufacturing and the advent of personalized therapies
- First acquisition by company since becoming Cytiva in April 2020
AMERSHAM, United Kingdom, Feb. 1, 2021 /PRNewswire/ Cytiva has acquired Vanrx Pharmasystems, a Canadian company that makes robotic aseptic filling machines to fill vials, syringes, and cartridges with reduced risk and increased speed to patients.
This is the first acquisition by Cytiva. Emmanuel Ligner, President and CEO, Cytiva, says: Since becoming a Danaher operating company in April 2020, we have already begun fueling innovation and re-investing in the business for the benefit of our customers and their patients. We are thrilled to welcome the Vanrx associates to our family and look forward to working together on delivering meaningful solutio